The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive -anxiety states. A controlled clinical trial.
The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive -anxiety states. A controlled clinical trial.
复制标题
单胺氧化酶抑制剂苯乙肼用于治疗抑郁焦虑状态。
DOI：
10.1001/archpsyc.1973.04200030093015
复制
发表时间：
1973
影响因子：
--
通讯作者：
K. Lamborn
中科院分区：
文献类型：
--
作者：
D. Robinson;A. Nies;C. Ravaris;K. Lamborn
在一项涉及87例非典型抑郁症门诊患者的前瞻性、对照、双盲实验中，比较单胺氧化酶（MAO）抑制剂、硫酸苯elzine和安慰剂。患者治疗6周，同时监测MAO抑制和症状严重程度。通过结构化的抑郁症访谈，精确地评估了抑郁症的类型和严重程度。60例患者完成了治疗期。治疗组根据年龄、性别、严重程度和抑郁症状类型等危险因素进行平衡。在16项前瞻性选择的测量中，苯乙肼完成者的改善在15项上大于安慰剂完成者。在易怒、疑病症-躁动和精神运动改变的亚量表得分上，苯苯肼的改善尤为显著。这些研究结果表明，MAO抑制剂可能对治疗具有非典型特征的抑郁症有特殊疗效，如焦虑、疲劳、恐惧症或其他躯体疾病。
The monoamine oxidase (MAO) inhibitor, phenelzine sulfate, and placebo were compared in a prospective, controlled, double-blind experiment involving 87 outpatients with features of atypical depression. Patients were treated for six weeks while MAO inhibition and symptom severity were monitored. By utilizing a structured depression interview, type and severity of depression were precisely assessed. Sixty patients completed the treatment period. Treatment groups were balanced for such risk factors as age, sex, severity, and type of depressive symptomatology. Improvement of phenelzine completers was greater than placebo completers for 15 out of 16 prospectively selected measures. Improvement in subscale scores for irritability, hypochondriasis-agitation, and psychomotor change was especially marked with phenelzine. These study findings suggest that MAO inhibitors may have a special efficacy in treating depressive illnesses with atypical features such as anxiety, fatigue, phobia, or other somatic complaints.